Why this matters now.
Zambia's pharmaceutical supply chain is being structurally rebuilt from the inside. The Zambia Medicines and Medical Supplies Agency (ZAMMSA) — working with the Global Fund, UNFPA, USAID, and WHO — completed forecasting and quantification planning for Zambia's 2026–2028 health commodity requirements in 2025. Drug availability at ZAMMSA's central hub has risen from 35% in 2021 to 68.3% by 2024; hospital availability reached 79%, and primary health centres 85% — against the WHO standard of 70%. Zambia's government committed K26.2 billion to the health sector in its 2026 budget — the largest ever allocation. ZAMRA is advancing a new Medicines and Allied Substances Bill (2026) to modernise the regulatory framework. Zambia is also moving toward local manufacture of 750 essential medicines. Mawadco Africa's pharmaceutical distribution work — anchored in Lusaka — sits directly in the last-mile delivery gap that these national programmes are working to close.
Supply gap and strategic context
Zambia's pharmaceutical supply chain has undergone significant reform since 2021. ZAMMSA's transition to central procurement management — previously fragmented across donors and ministries — has been the cornerstone of that reform. Essential drug availability at the ZAMMSA central hub stood at 35% in 2021; by 2024 it had risen to 68.3%. Hospital availability reached 79% and primary health centre availability 85%, measured against the WHO standard of 70%. Government budget allocation for essential drugs has grown from K1.4 billion in 2021 to K4.9 billion in 2025, with 19 additional procurement contracts signed. The 2026 national budget allocates K26.2 billion to the health sector — the largest ever commitment.
The structural challenge that remains is last-mile distribution. ZAMMSA's regional hubs represent a strong central node, but delivery reliability at the facility level — particularly in rural and peri-urban catchment areas — remains constrained by logistics infrastructure and cold-chain gaps. ZAMRA's 2026 Medicines and Allied Substances Bill introduces updated regulatory controls designed to close product quality and traceability gaps across the supply chain. Zambia's target to locally manufacture 750 essential medicines reduces import dependency over time — but the distribution infrastructure to move domestically produced medicines at scale requires private sector partners operating to international standards.
Mawadco Africa's distribution role
Mawadco Africa's pharmaceutical distribution work in Zambia targets the gap between ZAMMSA's central procurement and end-facility delivery reliability. Partner channels are being aligned around three priorities: supply continuity for essential healthcare products, documentation discipline to meet ZAMRA and international regulatory requirements, and cold-chain logistics coordination to support last-mile delivery where infrastructure constraints create consistent bottlenecks.
That operational focus mirrors the company's approach in mining and commodity trade — documentation-first, counterparty-verified, execution-led. As Zambia builds out its national pharmaceutical supply infrastructure over the coming decade — reducing import dependency and scaling domestic manufacturing — distribution capacity that meets international quality and compliance standards will remain the persistent constraint. Mawadco Africa is positioning its Lusaka-based partner network to serve that constraint directly.
Mawadco Africa publishes operational and market updates as programs develop. Media and partner enquiries: info@mawadco-africa.com or africa@mawadco.com
